224 related articles for article (PubMed ID: 18094217)
1. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion.
McSwain CS; Benza R; Shapiro S; Hill N; Schilz R; Elliott CG; Zwicke DL; Oudiz RJ; Staszewski JP; Arneson CP; Wade M; Zaccardelli D; McLaughlin V
J Clin Pharmacol; 2008 Jan; 48(1):19-25. PubMed ID: 18094217
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion.
Wade M; Baker FJ; Roscigno R; DellaMaestra W; Arneson CP; Hunt TL; Lai AA
J Clin Pharmacol; 2004 May; 44(5):503-9. PubMed ID: 15102871
[TBL] [Abstract][Full Text] [Related]
3. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.
Wade M; Baker FJ; Roscigno R; DellaMaestra W; Hunt TL; Lai AA
J Clin Pharmacol; 2004 Jan; 44(1):83-8. PubMed ID: 14681345
[TBL] [Abstract][Full Text] [Related]
4. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
[TBL] [Abstract][Full Text] [Related]
5. Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension.
Reisbig KA; Coffman PA; Floreani AA; Bultsma CJ; Olsen KM
Ann Pharmacother; 2005 Apr; 39(4):739-43. PubMed ID: 15755791
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
Benza RL; Gomberg-Maitland M; Naeije R; Arneson CP; Lang IM
J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577
[TBL] [Abstract][Full Text] [Related]
7. Initial experience using continuous intravenous treprostinil to manage pulmonary arterial hypertension in patients with end-stage liver disease.
Sakai T; Planinsic RM; Mathier MA; de Vera ME; Venkataramanan R
Transpl Int; 2009 May; 22(5):554-61. PubMed ID: 19175541
[TBL] [Abstract][Full Text] [Related]
8. Treprostinil for pulmonary hypertension.
Vachiéry JL; Naeije R
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
[TBL] [Abstract][Full Text] [Related]
9. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ
Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous and Intravenous Treprostinil Pharmacokinetics in Children With Pulmonary Vascular Disease.
Hall K; Ogawa M; Sakarovitch C; Hopper RK; Adamson GT; Hanna B; Ivy DD; Miller-Reed K; Yung D; McCarthy E; Siehr-Handler SL; Feinstein JA
J Cardiovasc Pharmacol; 2019 Jun; 73(6):383-393. PubMed ID: 31162247
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension.
White RJ; Torres F; Allen R; Jerjes C; Pulido T; Yehle D; Howell M; Laliberte K; Marier JF; Tapson VF
J Cardiovasc Pharmacol; 2013 Jun; 61(6):474-81. PubMed ID: 23328389
[TBL] [Abstract][Full Text] [Related]
12. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
14. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(8):170-2. PubMed ID: 17332729
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension.
de Jesus Perez VA; Rosenzweig E; Rubin LJ; Poch D; Bajwa A; Park M; Jain M; Bourge RC; Kudelko K; Spiekerkoetter E; Liu J; Hsi A; Zamanian RT
Am J Cardiol; 2012 Nov; 110(10):1546-50. PubMed ID: 22853986
[TBL] [Abstract][Full Text] [Related]
16. Rapid Inpatient Titration of Intravenous Treprostinil for Pulmonary Arterial Hypertension: Safe and Tolerable.
El-Kersh K; Ruf KM; Smith JS
Am J Ther; 2018; 25(2):e213-e217. PubMed ID: 27003321
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers.
Jones A; Wang-Smith L; Pham T; Laliberte K
J Cardiovasc Pharmacol; 2014 Mar; 63(3):227-32. PubMed ID: 24603117
[TBL] [Abstract][Full Text] [Related]
18. High incidence of bloodstream infection due to gram-negative bacilli in patients with pulmonary hypertension receiving intravenous treprostinil.
López-Medrano F; Fernández-Ruiz M; Ruiz-Cano MJ; Barrios E; Vicente-Hernández M; Aguado JM; Escribano P
Arch Bronconeumol; 2012 Dec; 48(12):443-7. PubMed ID: 22858303
[TBL] [Abstract][Full Text] [Related]
19. Treprostinil for the treatment of pulmonary arterial hypertension.
Torres F; Rubin LJ
Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations.
Mathier MA; McDevitt S; Saggar R
J Heart Lung Transplant; 2010 Nov; 29(11):1210-7. PubMed ID: 20855220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
